Evidence map›Paper›PMID 36412082›Full record

ArticlePigment cell & melanoma research2023

Genetically engineered multicistronic allele of Pmel yielding highly specific CreERT2-mediated recombination in the melanocyte lineage.

Emma L Wilkinson, Louise C Brennan, Olivia J Harrison, Zoe Crane-Smith, Philippe Gautier, Margaret A Keighren, Peter Budd, Karthic Swaminathan, Laura M Machesky, Sarah L Allinson and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Pigment cell & melanoma research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Emma L WilkinsonDivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.ORCID 0000-0002-7261-3338
Louise C BrennanDivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.ORCID 0000-0003-0324-2665
Olivia J HarrisonMRC Human Genetics Unit, Institute of Genetics and Cancer, Western General Hospital, University of Edinburgh, Edinburgh, UK.ORCID 0000-0003-4470-5304
Zoe Crane-SmithMRC Human Genetics Unit, Institute of Genetics and Cancer, Western General Hospital, University of Edinburgh, Edinburgh, UK.ORCID 0000-0003-0738-6148
Philippe GautierMRC Human Genetics Unit, Institute of Genetics and Cancer, Western General Hospital, University of Edinburgh, Edinburgh, UK.ORCID 0000-0003-3019-6262
Margaret A KeighrenMRC Human Genetics Unit, Institute of Genetics and Cancer, Western General Hospital, University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-8116-9670
Peter BuddMRC Human Genetics Unit, Institute of Genetics and Cancer, Western General Hospital, University of Edinburgh, Edinburgh, UK.ORCID 0000-0001-8951-2413
Karthic SwaminathanCentre for Skin Sciences, Faculty of Life Sciences, University of Bradford, Bradford, UK.ORCID 0000-0002-0981-7549
Laura M MacheskyCancer Research UK, Beatson Institute, and Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-7592-9856
Sarah L AllinsonDivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.ORCID 0000-0003-1937-5550
Ian J JacksonMRC Human Genetics Unit, Institute of Genetics and Cancer, Western General Hospital, University of Edinburgh, Edinburgh, UK.ORCID 0000-0001-6526-0688
Richard L MortDivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.ORCID 0000-0002-3566-8217
Western General Hospital · GBLancaster University · GBCancer Research UK Scotland Institute · GBRoslin Institute · GBUniversity of Bradford · GB

Funding

Cancer Research UK 24452Cancer Research UK A15673Cancer Research UK DRCRPG-NOV22/100017Medical Research Council MC_PC_U127527200Medical Research Council MC_UU_00007/4National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/K001612/1
6 · The paper itself

Abstract

Genetic approaches that allow lineage tracing are essential to our future understanding of melanocytes and melanoma. To date, the approaches used to label melanocytes in mice have relied on random integration of transgenes driven by the promoters of the Tyrosinase and Dopachrome tautomerase genes, knock-in to the Dopachrome tautomerase locus or knock-in to the Mlana locus in a bacterial artificial chromosome. These strategies result in expression in other tissues such as telencephalon and other cell types such as nerves. Here we used homologous recombination in mouse embryonic stem cells to generate a targeted multicistronic allele of the Pmel locus that drives melanocyte-specific expression of CreERT2, nuclear localised H2B-Cerulean and membrane localised marcks-mKate2 allowing live imaging of melanocytes and activation of other conditional alleles. We combined this allele with R26R-EYFP mice allowing induction of EYFP expression on administration of tamoxifen or its metabolite 4-OHT. The fluorescent proteins H2B-Cerulean and marcks-mKate2 label the cell nucleus and plasma membrane respectively allowing live imaging and FACS isolation of melanoblasts and melanocytes as well as serving to provide an internal control allowing estimation of recombination efficiency after administration of tamoxifen. We demonstrate the utility of the transgene in embryonic and adult tissues.

Indexed as

MelanocytesMelanomaAllelesAnimalsMiceMice, TransgenicTamoxifenTamoxifenkeratinocytesmelanoblastsmelanocytesmelanoma

Identifiers

PMID36412082
PMCPMC10107733
OpenAlexW4309656600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.